You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A molecularly targeted pre- and post-exposure vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use However for reasons of safety convenient empirical use and cost the development of broader spectrum antibiotics rapidly supplanted the use of immune serum But drug resistance is quickly reducing th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: Protein Metrics Inc.            Topic: 300

    DESCRIPTION provided by applicant This project addresses the need for better methods for deciphering the glycosylation of proteins in clinical samples Glycosylation is an important modifier of protein structure and function and contributes to disease processes But we currently know little about the glycosylation of most proteins The current methods for probing glycans on proteins are not su ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GENECAPTURE            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  8. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnos

    SBC: Lucira Health, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Detecting Chlamydia Ct STIs at the point of care POC represents a critical unmet medical need Development of an effective Ct POC diagnostic will result in widespread screening efforts for rapid diagnosis to inform treatment and evaluate treatment efficacy and for test of cure that would not only reduce the acute and chronic morbidity that is directly asso ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government